Short answer
Personalis, Inc. (PSNL) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Personalis announced financial results for the quarter ended September 30, 2026.
Personalis, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Personalis announced financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, cash position and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $25.6M, up from $14.5M, driven by clinical testing, pharma services and population sequencing
- Clinical volume 13,157 tests versus 4,388, with clinical revenue rising to $4.4M from $0.4M
- Pharma testing revenue $17.1M, while population sequencing reached $4.1M versus $0.2M
- Net loss widened to $33.8M, or $0.32 per share, from $21.7M, or $0.24 per share
- Cash, equivalents and short-term investments $190.6M, while pending Tempus merger eliminates 2026 financial guidance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Personalis, Inc. 8-K filings
Get the next PSNL 8-K as it lands
Follow PSNL for push alerts, or ask the research agent what this filing means.